Sublingual and buccal administration of selegiline
CA 2236368 C · Owner: Disanto, Anthony R. · Inventors: Disanto, Anthony R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to improved methods for treating certain selegiline-responsive diseases or conditions and more specifically, to , methods in which selegiline is administered buccally or sublingually. Selegiline may be used either as a free base or as a pharmaceutically acceptable acid addition salt. The selegiline-responsive diseases or conditions include neuronal-degenerative diseases and conditions such as , Alzheimer's disease and neuronal damage from hypoxia stroke, ischemia, and , trauma, and dopaminergic-related selegiline responsive diseases and , conditions such as depression and ADHD.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 5, 1996 and granted October 23, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 5, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 5, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.